Evidence map›Paper›PMID 18596623›Full record

Trial reportCritical care medicine2008

Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome.

Ednan K Bajwa, James L Januzzi, Michelle N Gong, B Taylor Thompson, David C Christiani

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Critical care medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ednan K BajwaPulmonary and Critical Care Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ebajwa@partners.org
James L Januzzi
Michelle N Gong
B Taylor Thompson
David C Christiani
Harvard University Press · USHarvard University · USIcahn School of Medicine at Mount Sinai · US

Funding

MOLECULAR EPIDEMIOLOGY OF ARDSR01HL060710 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 2000 to 2015
$8.4M
TRAINING GRANT IN LUNG CELL &MOLECULAR BIOLOGYT32HL007874 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MEDOFF, BENJAMIN DAVID · 1997 to 2011
$4.1M
Molecular Epidemiology of ARDS and Septic ShockK23HL067197 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GONG, MICHELLE NG · 2001 to 2005
$650k
NHLBI NIH HHS HL07874NHLBI NIH HHS HL60710NHLBI NIH HHS HL67197NHLBI NIH HHS K23 HL067197NHLBI NIH HHS R01 HL060710NHLBI NIH HHS T32 HL007874
6 · The paper itself

Abstract

objectivePatients with acute respiratory distress syndrome suffer from profound cardiac and pulmonary derangement, including right ventricular strain and noncardiogenic pulmonary edema, which may potentially alter concentrations of cardiac natriuretic peptides. We sought to determine whether N-terminal probrain natriuretic peptide (NT-proBNP) levels are elevated in acute respiratory distress syndrome and whether they can serve as a marker of prognosis in this setting.

designProspective study.

settingTertiary-care academic medical center. PATIENTS: One hundred seventy-seven acute respiratory distress syndrome subjects enrolled in a prospective intensive care unit cohort.

interventionsNone. MEASUREMENTS AND MAIN

resultsNT-proBNP was measured from blood taken within 48 hrs of acute respiratory distress syndrome onset. Patients were followed for the primary outcome of 60-day mortality and secondary outcomes of organ dysfunction and ventilator-free days. Seventy patients died (40%). Median NT-proBNP level was 3181 ng/L (interquartile range 723-9246 ng/L). NT-proBNP levels were significantly higher among nonsurvivors (p < .0001). Receiver operating curve analysis revealed an optimal NT-proBNP cut-point of 6813 ng/L for predicting death. Patients with levels above the cut-point had significantly higher odds of mortality on multivariable analysis (odds ratio 2.36, 95% confidence interval 1.11-4.99, p = .02) than those with levels below the cut-point. Kaplan-Meier survival analysis showed that this difference emerged early and was sustained (p < .0001). Patients with elevated NT-proBNP also had higher organ dysfunction scores (p < .0001) and fewer ventilator free days (p = .03) than those with lower NT-proBNP levels.

conclusionsNT-proBNP levels are elevated among acute respiratory distress syndrome patients and parallel the severity of the syndrome and likelihood for morbidity and mortality. This demonstrates the potential utility of this biomarker for prognosis in this disease.

Indexed as

AgedAPACHEBiomarkersFemaleHumansIntensive Care UnitsLogistic ModelsMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisProspective StudiesRespiratory Distress SyndromeSurvival AnalysisBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID18596623
PMCPMC3106101
OpenAlexW2142276326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.